ATE467124T1 - Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung - Google Patents

Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung

Info

Publication number
ATE467124T1
ATE467124T1 AT03754894T AT03754894T ATE467124T1 AT E467124 T1 ATE467124 T1 AT E467124T1 AT 03754894 T AT03754894 T AT 03754894T AT 03754894 T AT03754894 T AT 03754894T AT E467124 T1 ATE467124 T1 AT E467124T1
Authority
AT
Austria
Prior art keywords
prp
molecules interacting
sup
peptides
features
Prior art date
Application number
AT03754894T
Other languages
German (de)
English (en)
Inventor
Neil Cashman
Eustache Paramithiotis
Boissiere Sylvie La
Robert Lawton
Greg Francoeur
Lisa Estey
Marc Pinard
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Application granted granted Critical
Publication of ATE467124T1 publication Critical patent/ATE467124T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03754894T 2002-09-27 2003-09-26 Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung ATE467124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/256,538 US20040072236A1 (en) 2002-09-27 2002-09-27 PrPSc -interacting molecules and uses thereof
PCT/US2003/030273 WO2004029072A2 (en) 2002-09-27 2003-09-25 PrPsc -INTERACTING MOLECULES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE467124T1 true ATE467124T1 (de) 2010-05-15

Family

ID=32041771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03754894T ATE467124T1 (de) 2002-09-27 2003-09-26 Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung

Country Status (7)

Country Link
US (2) US20040072236A1 (OSRAM)
EP (1) EP1575989B1 (OSRAM)
JP (1) JP4533750B2 (OSRAM)
AT (1) ATE467124T1 (OSRAM)
CA (1) CA2500120A1 (OSRAM)
DE (1) DE60332488D1 (OSRAM)
WO (1) WO2004029072A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
CA2448981C (en) 2001-05-31 2014-03-18 Arete Associates Misfolded protein sensor method
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
CN1806053A (zh) * 2003-04-14 2006-07-19 美国红十字会 对蛋白的结构同工型特异的配体的鉴定方法
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
DK1653844T3 (da) 2003-08-13 2013-03-11 Novartis Vaccines & Diagnostic Prionspecifikke peptidreagenser
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US7328063B2 (en) * 2004-11-30 2008-02-05 Cardiac Pacemakers, Inc. Method and apparatus for arrhythmia classification using atrial signal mapping
NZ587255A (en) * 2005-01-13 2012-03-30 Novartis Vaccines & Diagnostic Elisa assays using prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US8372593B2 (en) * 2005-02-15 2013-02-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
NZ566020A (en) * 2005-09-09 2012-08-31 Novartis Ag Prion-specific peptoid reagents
JP4769925B2 (ja) * 2006-03-15 2011-09-07 国立大学法人東北大学 異常型プリオン蛋白質の濃縮方法、および除去方法
US7601506B2 (en) * 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
AU2007277186B2 (en) * 2006-07-28 2014-01-30 Presympto, Inc. Peptide probes for diagnostics and therapeutics
JP2010515879A (ja) * 2007-01-12 2010-05-13 オールプリオン・アーゲー プリオンタンパク質を取り出すための方法
EP2279203B1 (en) 2008-04-25 2016-06-15 University Of Saskatchewan Prion epitopes and methods of use thereof
WO2009134942A1 (en) * 2008-04-30 2009-11-05 Novartis Ag. Assay for pathogenic conformers
US20120009209A1 (en) * 2010-06-10 2012-01-12 The Regents Of The University Of California Enrichment and purification of infectious prion proteins
US8945860B2 (en) 2010-09-13 2015-02-03 Abbvie Inc. Highly sensitive monoclonal antibody residual detection assay

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
WO1987006706A1 (en) 1986-04-30 1987-11-05 Igen, Inc. Electrochemiluminescent assays
SU1529119A1 (ru) 1987-04-20 1989-12-15 Белорусский научно-исследовательский институт эпидемиологии и микробиологии Способ определени нейровирусов в спинномозговой жидкости
US4806627A (en) * 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
AU9028791A (en) 1990-10-05 1992-04-28 President And Fellows Of Harvard College Detection and isolation of ligands
CA2095115A1 (en) 1990-10-30 1992-05-01 Barbara Ranscht T-cadherin adhesion molecule
ES2128362T3 (es) * 1991-12-03 1999-05-16 Proteus Molecular Design Fragmentos de proteinas de prion.
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
WO1993021302A1 (en) * 1992-04-17 1993-10-28 Doheny Eye Institute Cadherin materials and methods
WO1993023432A1 (en) 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5643781A (en) * 1992-12-29 1997-07-01 Doheny Eye Institute DNA encoding protocadherin-42
US5798224A (en) 1992-12-29 1998-08-25 Doheny Eye Institute Nucleic acids encoding protocadherin
US5679530A (en) * 1995-04-12 1997-10-21 Ludwig Institute For Cancer Research Isolated protein having molecular weight of from about 55 kilodaltons to about 65 kilodaltons (SDS-page) which binds to prion protein
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
DE852011T1 (de) 1995-09-14 2001-10-11 Scripps Res Inst La Jolla Für natives prp-sc spezifische antikörper
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
JP3745380B2 (ja) * 1996-05-14 2006-02-15 ヴィンアッカー，エルンスト―ルートヴィッヒ プリオンタンパク質に結合し、イソ型ＰｒＰ▲上ｃ▼とＰｒＰ▲上ｓｃ▼を識別することが可能なシャペロン
EP0920630B1 (en) * 1996-05-29 2002-07-31 McGILL UNIVERSITY Prion binding proteins and uses thereof
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
US6165784A (en) 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
EP1057022B1 (en) 1998-02-20 2003-07-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
GB2348203B (en) * 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
NZ516240A (en) * 1999-06-23 2005-11-25 Caprion Pharmaceuticals Inc Prion protein peptides and uses thereof
JP2003531356A (ja) * 1999-06-29 2003-10-21 マクギル ユニバーシティー プリオンタンパク質結合タンパク質及びそれらの使用
CA2405568A1 (en) * 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof

Also Published As

Publication number Publication date
EP1575989B1 (en) 2010-05-05
CA2500120A1 (en) 2004-04-08
AU2003272695A1 (en) 2004-04-19
WO2004029072A2 (en) 2004-04-08
US7435540B2 (en) 2008-10-14
EP1575989A4 (en) 2007-05-16
JP2006507484A (ja) 2006-03-02
EP1575989A2 (en) 2005-09-21
US20040072236A1 (en) 2004-04-15
JP4533750B2 (ja) 2010-09-01
US20060183156A1 (en) 2006-08-17
WO2004029072A3 (en) 2005-12-15
DE60332488D1 (de) 2010-06-17

Similar Documents

Publication Publication Date Title
ATE467124T1 (de) Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung
ATE541590T1 (de) Modifizierte antikörper-fragmente
DE60032486D1 (de) Prion protein peptide und deren verwendung
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
WO2005003171A3 (en) Modified antibody fragments
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
EP1480657A4 (en) POLYMERS FOR ADMINISTERING PEPTIDES AND SMALL MOLECULES IN VIVO / I
EP1912674A4 (en) BIS SPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHOD OF USE THEREOF
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
ATE382053T1 (de) System zur antikörperexpression und- synthese
ATE424560T1 (de) Marker für neuromyelitis optica
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
DE60207254D1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ATE466870T1 (de) Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof
DE60334400D1 (de) Neue polynukleotid- und polypeptidsequenzen und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties